ProCE Banner Activity

KEYNOTE-716: Update of the Phase III Trial of Adjuvant Pembrolizumab vs Placebo in Stage IIB/IIC Melanoma

Slideset Download
Conference Coverage
Results through 27.4 months of follow-up continue to support the benefit of adjuvant pembrolizumab in reducing the risk of recurrence and distant metastasis in patients with stage IIB/IIC melanoma.

Released: June 10, 2022

Expiration: June 09, 2023

No longer available for credit.
Begin Activity


Provided by

Provided by Clinical Care Options, LLC
ProCE Banner


Supported by educational grants from



Bristol Myers Squibb

Daiichi Sankyo, Inc.

Gilead Sciences, Inc.


Jazz Pharmaceuticals Inc

Merck Sharp & Dohme Corp.

Novartis Pharmaceuticals Corporation

Seagen and Genmab